Thiolactomycin
Latest Information Update: 25 Jan 2008
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; St. Jude Childrens Research Hospital
- Class Antibacterials
- Mechanism of Action Fatty acid synthetase complex inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Tuberculosis
Most Recent Events
- 25 Jan 2008 Discontinued - Preclinical for Tuberculosis in USA (unspecified route)
- 10 Dec 2002 This compound is still in active development
- 26 Mar 2001 Preclinical development for Tuberculosis in USA (unspecified route)